Cell & Gene Therapy in 2026 is no longer an experimental corner of biotechnology.
It is rapidly becoming a large-scale industrial healthcare system, built around manufacturing, automation, and global delivery of living medicines.
What is changing fundamentally is the nature of the industry itself.
It is shifting from “developing therapies in labs” to “producing personalized treatments at industrial scale.”
The CAR-T space is one of the clearest examples of this transformation.
The global CAR-T market has already reached multi-billion-dollar scale (~$5–6B range) and continues to grow at a strong double-digit rate.
This is important because CAR-T therapies are not traditional drugs.
Each treatment is made from a patient’s own cells, meaning every dose requires a full manufacturing cycle.
Companies like CARsgen Therapeutics show how scale is being achieved in real terms.
They operate a multi-site manufacturing system across China and the U.S., collectively capable of handling thousands of patients per year.
Their facilities are designed like production hubs rather than research labs.
With high manufacturing success rates (above 95%), the focus is now on consistency, not just discovery.
Commercial adoption is also beginning to show up in revenue data.
Autolus Therapeutics has reported around US$74.3 million in annual product revenue (FY2025).
While still early-stage compared to traditional pharma giants, this reflects a key shift: CAR-T therapies are now being used in real hospital settings at scale.
In cell therapy, revenue is directly linked to treated patients.
So even modest revenue indicates meaningful clinical adoption.
In solid tumor therapies, Iovance Biotherapeutics is a major milestone case.
The company has now treated 700+ patients using TIL (Tumor-Infiltrating Lymphocyte) therapy.
This is significant because solid tumors are much harder to treat than blood cancers.
Reaching hundreds of treated patients shows that these therapies are moving beyond clinical trials into real-world oncology use.
Another major driver of this industry is manufacturing infrastructure.
Companies are now building extremely large GMP-certified facilities dedicated to cell therapy production.
For example, Celularity Inc. operates a facility of over 147,000 square feet, designed specifically for allogeneic cell therapy manufacturing.
This reflects a major shift in mindset:
therapies are no longer handcrafted—they are being factory-produced under pharmaceutical-grade systems.
Big pharmaceutical companies are also entering aggressively through acquisitions and partnerships.
Deals worth multi-billion dollars (often $1B–$7B range) are becoming common for gene therapy and cell therapy platforms.
This shows that large pharma companies now see CGT as a core future pillar, not a niche investment area.
They are not just buying drugs—they are buying technology platforms, manufacturing capabilities, and scalable pipelines.
The regulatory environment is also accelerating adoption.
Globally, there are now dozens of approved cell and gene therapy products, with major leadership coming from the U.S. and China.
CAR-T approvals alone have expanded steadily across both regions, reflecting faster acceptance of advanced therapies in oncology care systems.
At the same time, global cancer drug spending has crossed hundreds of billions of dollars annually, creating a massive demand base for advanced therapies.
What makes this even more important is that the industry is expanding beyond cancer.
Cell and gene therapies are now moving into:
- autoimmune diseases
- rare genetic disorders
- retinal and neurological conditions
- regenerative medicine applications
This means the addressable market is expanding far beyond oncology.
The competitive landscape includes major players such as
Novartis, Kite Pharma, Bristol Myers Squibb, CRISPR Therapeutics, Legend Biotech, bluebird bio, and Johnson & Johnson.
Each company is working on different parts of the ecosystem:
- gene editing technologies
- CAR-T and T-cell therapies
- viral vector systems
- scalable manufacturing platforms
- global commercialization networks
The biggest shift in this industry is not scientific anymore—it is operational.
Earlier, success meant discovering a working therapy.
Now, success means delivering that therapy reliably to thousands of patients across the world.
We provide a platform where market insights, competitor strategies, and stats come together. Just log in to the dashboard and get all the information you need, without any hassle: https://www.towardshealthcare.com/cell-gene-intelligence-platform
That requires solving real-world constraints like:
- manufacturing speed
- supply chain stability
- regulatory approvals
- hospital integration
- cost reduction per treatment
In simple terms, Cell & Gene Therapy is becoming a new industrial category inside healthcare.
Not just drug development—but a manufacturing-driven system for living medicines.
And the companies that master scale, not just science, will define the future of global medicine.
Access our exclusive, data-rich dashboard dedicated to the cell and gene therapy – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare Research and Consulting is a global insights and strategy partner focused on advancing cell and gene therapy innovation. We support biotech firms and healthcare leaders with clinical research expertise, data-driven analytics, and strategic consulting. Our goal is to accelerate the development and delivery of next-generation genetic therapies by transforming complex science into actionable, real-world solutions.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium